The Awards recognise the most promising start-up brands that are set to boost the economy of the country
SuperStartUps India, a platform to recognise the innovation and efforts of the start-ups in the country, today announced its first ever list of winners. A venture from the house of Superbrands, the coveted multinational brand endorser, recognised 32 brands from across sectors for their vision and contribution to this growing industry.
The winners include Melora, Monexo, Transcell, Prop Tiger, Canvs, Cloudacar, Clayplay, Imithila, Vaayu India, Medisponsor, Innov8, ExtraCarbon, Zivame, Licious, Rentickle, Milkbasket, Khanagadi, Drivify, IndusOS, Rxpress, Housejoy, Sheroes, Schoolwear, Squareyards, Orahi, Byjus, World Art Community, Faircent, Dogsee Chew, Parentune, Bluestone and Shopclues.
With the growing trend of creating a start-up instead of taking the traditional route has swept India away in recent times. Government incentives and an influx of capital from abroad have made it increasingly attractive to take that big leap of faith. Taking accord of this tectonic shift in Indian business culture, SuperStartUps was designed to heap acclaim on all the start-ups spending night and day trying to make the next ubiquitous, innovative offering.
Shivjeet Kullar, Head of SuperStartUps awards said, “India is fast rising as the start-up destination in the world. With the rapid expansion of the start-up culture in the country, it becomes imperative to identify and acknowledge the brands who not just have taken the offbeat route but are continuing to chase their destination differently.”
“The winners have been chosen by the netizens of India and we hope and wish that the tag of being a SuperBrand winner will help them grow further,” he added.
Not only was the programme unique since its inception – it was also totally impartial. The winning SuperStartUps were not decided by any panel of judges but by the citizens or rather netizens of India. Across 15 metros and smaller cities from all parts of India constituted a confidential panel of thousands of ‘voters’ that chose the online brands they prefer.
Chosen out of a vast pool of 2000 applications, the winning start-ups will be free to avail all associated facilities like profiling of the firm in the annual SuperStartUps book and to be able to use the ‘Superbrand’ status for a year in all its communications. A badge of honour for the creme de la creme of the start-up world, the award has rolled out first in India – currently the ‘start–up capital of the world’.
The monitoring council of the project included Dar and Adman Prahlad Kakkar, Valerie Pinto, Chief Executive Officer (CEO) of Weber Shandwick; Sanjeev Bikhchandani, Founder of Info Edge, and Deep Kalra, Founder and CEO of MakeMyTrip.
SuperStartUps started with a vision of providing something of incredible value to its winners that sets itself apart from other start-up competitions – a start-up competition chosen by the netizens of India. At the end of the day, the success of a start-up depends on how resonant its product is among the masses. With this, SuperStartUps decided to undertake an extensive research process encompassing 4 months and 22 Indian cities to ascertain which start-ups were making the most buzz.
Finally, from over 6000 eligible start-ups, India’s next big start-ups were selected. Being a SuperStartUp provides its winners the ultimate validation – how the public is reacting to their idea. Accompanied by a research report, they get a holistic understanding of what aspects of their business are working and what needs to be tweaked to provide a product that is universally lauded. Furthermore, they get access to the who’s who of the investor world to secure funding for expanding their operations.
Lastly, they get the stamp of being the first SuperStartUps by Superbrands – an organization that has successfully provided a differentiating factor for all the companies it has honored in its 15-year stint in India.
Medically Approved Regenerative Treatments Using Dental Stem Cells
Teeth, which happen to be the most natural and noninvasive source of stem cells owing to their convenience and affordability to collect hold promise for a range of difficult to treat medical indications. The regenerative capacity of dental pulp derived stem cells has been a topic of utmost interest to clinicians and researchers alike in the field of regenerative medicine. The story of dental stem cells dates back to 2003, when Dr. Songtao Shi, a pedodontist discovered baby tooth stem cells in the deciduous teeth of his six year old daughter and named the cells as stem cells from the human exfoliated deciduous teeth (SHED). Dental Pulp Stem Cells or DPSCs as they are commonly referred to, are found within the ‘‘cell rich zone’’ of the dental pulp. Their multipotent nature can be attributed to their origin from the neural crest. Owing to their multipotent nature, these DPSCs can effectively differentiate into many cell types which include adipocytes, neurons, chondrocytes and mesenchymal stem cells under specific stimuli. Since they can be found in both adults and children alike, their use in regenerative and patient specific treatment of certain ailments has been gaining rapid momentum. One of the major advantages of DPSCs over umbilical cord/blood stem cells is that the dental stem cells are derived from the deciduous and permanent teeth (wisdom/corrective) and can be collected later after birth unlike their umbilical cord counterparts. Collection of teeth for dental pulp and isolation of stem cells from the pulp can be carried out without raising any ethical red flags as the procedure is very simple/non-invasive without any associated mortality or morbidity. Recent advances in the field of dental stem cell clinical research have made it possible to employ them in reparative and regenerative roles. This newsletter is an effort to bring to the reader’s attention some of major advancements in the “close to reality of DPSCs in clinics”. We hope the reader while appreciating the significance of DPSCs would strongly consider storing their loved ones’ about to fall milk teeth derived stem cells even if the loved ones Cord/blood were banked as the medically approved applications are different for different sources.
Anand Ram Soorneedi
TOOTH (The Open study Of dental pulp stem cell Therapy in Humans): Study protocol for evaluating safety and feasibility of autologous human adult dental pulp stem cell therapy in patients with chronic disability after stroke
Stroke represents a significant global disease burden. As of 2015, there is no chemical or biological therapy proven to actively enhance neurological recovery during the chronic phase post-stroke. Human adult dental pulp stem cells present an exciting potential therapeutic option for improving post-stroke disability. TOOTH (The Open study Of dental pulp stem cell Therapy in Humans) will investigate the use of autologous stem cell therapy for stroke survivors with chronic disability, with the following objectives: (a) determine the maximum tolerable dose of autologous dental pulp stem cell therapy; (b) define that dental pulp stem cell therapy at the maximum tolerable dose is safe and feasible in chronic stroke; and (c) estimate the parameters of efficacy required to design a future Phase 2/3 clinical trial. The primary outcomes to be measured are safety and feasibility of intracranial administration of autologous human adult DPSC in patients with chronic stroke and determination of the maximum tolerable dose in human subjects. Secondary outcomes include estimation of the measures of effectiveness required to design a future Phase 2/3 clinical trial.
Human dental pulp stem cells (hDPSCs) as treatment for periodontal disease
ISRCTN12831118 DOI 10.1186/ISRCTN12831118
Periodontitis, or periodontal disease (PD) is a very common chronic gum infection that damages the soft tissue and destroys the bone supporting the teeth. It can lead to tooth loss, difficulties chewing, poor appearance of teeth and gums and it can even increase the risk of a heart attack or stroke. It is caused by the build-up of bacteria in the mouth which, over time, combines with saliva and small food particles to form a sticky film over the teeth, called plaque. The bacteria in the plaque can result in gum disease, leading to swollen, painful gums. If not treated, this gum disease will get worse and will develop into periodontitis. Up to 90% of people over the age of 75 have PD and it carries with it a high risk of other health complications. Current treatments are not very effective. Experimental and clinical data suggest that human dental pulp stem cells (hDPSCs) are capable of regenerating periodontal structures (soft tissues and bone supporting the teeth) regardless of their autologous (coming from the person themselves) or allogeneic origin (coming from a donor). This study is looking at the effect of in situ treatment with hDPSCs on periodontal disease, markers of oxidative stress and inflammation in aging adults.
Feasibility of the Preparation of an Advanced Therapy Medicinal Product for Dental Pulp Regeneration (Pulp’R)
ClinicalTrials.gov Identifier: NCT02842515
Current endodontic treatments are based essentially on the ouster of parenchyma in case of trauma or irreversible pulp inflammation. These situations typically affect immature teeth in subjects aged from 8 to 15 years. Consequently, loss of a functional pulp is leads to discontinuation of root development and apical closure. The challenge for the clinician in the management of such situations is then preserving a pulp vitality. But current practices consist in a filling of the endo-canal system with an inert or semi-inert material. In this case, no pulp vitality is present. New treatment methods are needed. The objective Pulp’R is the study the feasibility of preparing an autologous combined advanced therapy medicinal product (ATMP) for dental pulp regeneration in the patient with irreversible pulp inflammation or dental trauma.
Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy
The purpose of this study is to evaluate the safety of clinical injection of allogeneic human dental pulp stem cell (DPSC) in local infected periodontal tissue and determine whether injection of allogeneic DPSC is a effective way in the treatment of chronic periodontal disease.
3D printing has been touted as one of the most disruptive technologies that have been making waves during the 21st century. Despite some initial negative press about the technology, it has been quickly catching up generating a lot of buzz in the industry and general public alike. 3D printing is also called additive manufacturing wherein three dimensional solid objects are produced by laying down successive layers of material until the object is created. Each of these layers can be seen as a thinly sliced horizontal cross-section of the eventual object. The ease of access to 3D templates, scanners, modeling software and printers that can print 3D objects has made our lives much easier.
From printing daily objects like furniture to complicated structures such as airplane and space shuttle parts, this rather exciting new technology slowly started becoming an integral part of our lives. According to Wohlers Report 2014, the worldwide 3D printing industry is now expected to grow from $3.07B in revenue in 2013 to $12.8B by 2018, and exceed $21B in worldwide revenue by 2020. The healthcare industry has quickly realized the full potential of this technology and researchers and clinicians are taking steps towards harnessing the power of 3D printing in improving the quality of human life. In the field of healthcare, 3D printing can be used in developing prosthetics, dental and bone implants, medical instruments, tissue and simple printed organs that can be used in transplants, pharmaceuticals production, nano-scale medicine and also in the printing of complex organs. As we are already aware of the Stem cells’ unique ability to produce both copies of themselves (self-renewal) and other more specialized cell types (differentiation) every time they divide, it would be exciting to see the marriage of stem cell therapy with 3D printing technology.
This newsletter is an effort to educate the reader about the potential applications of 3D printing technology using stem cells.
I am confident that the reader while appreciating the technological marvel that is 3D printing technology would also realize the potential of applying this technology in stem cell based regenerative therapies.
Nano Dimension Announces New 3D Bioprinting Subsidiary to Develop
Solutions fo rend Stage Renal Disease
Israel-based company Nano Dimension has a new announcement: the 3D printed electronics leader is creating a new subsidiary in order to advance its new 3D bioprinting initiative. In early 2016, the company partnered with Accelta, a stem cell culturing solutions provider, to successfully lab-test a proof of concept 3D bioprinter for producing stem cell-derived tissues.
Nano Dimension has been conducting market research into applications of its 3D bioprinting technology, and says that it will now be developing a platform to 3D bioprint both connective tissues and cells, which will be used to create biological structures that will function as human kidneys. The subsidiary will focus mainly on developing solutions for end stage renal diseases (ESRD) which ultimately lead to kidney failure.
3D bioprinted myocardial path could boost heart attack recover,
Korean Researchers say
A team of researchers in Korea has used a 3D bioprinter to make a myocardial therapeutic patch for treating ischemic heart disease. When attached to the heart, the 3D printed patch can generate new blood vessels and tissues. Professor Park Hoon-joon of the Seoul St. Mary’s Hospital and professor Jo Dong-woo of the Pohang University of Science & Technology, two of the lead researchers on the exciting bioprinting study, announced the results of their research on February 9, claiming that their 3D printed myocardial patch could radically change the way doctors approach the treatment of ischemia, a condition that results in low blood supply to the heart muscles or other organs.
To create the 3D printed heart patch, the researchers used cardiac extracellular matrices as a 3D printable bioink, with cardiac stem cells and mesenchymal stem cells configured in a double-cell arrangement. A vascular endothelial growth factor (VEGF), a signal protein that stimulates vasculogenesis and angiogenesis, was also introduced. The researchers say that this complex arrangement could hold the key to recovery from ischemic heart disease—at present, the five-year survival rate for patients is less than 50 percent.
Soon Printing a human heart on demand will no longer be sci-fi
Around the world, start-ups — like Tokyo-based Cyfuse Biomedical — are emerging to develop such breakthroughs in the field of regenerative medicine. It is a market projected to reach $101.3 billion by 2022.
Unlike conventional medicines and treatments, regenerative medicines have the ability to restore or heal the body’s own cells or create new body parts from a patient’s own cells and tissues, thereby eliminating tissue rejection and the excessively long wait for a donor organ. This would be a remarkable scientific achievement, considering that in the United States alone 118,950 people are registered in the Organ Procurement Transplantation Network. Of these candidates, 22 die each day waiting for a lifesaving organ. The gap between supply and demand continues to widen, and it’s a problem many medical experts have called a major health crisis. Cyfuse has also started a clinical trial of a cartilage project, transplanting its stem cell construct into damaged articular cartilage that will gradually differentiate into cartilage and bone and regenerate the tissue. Cyfuse is one of a growing number of tech start-ups trying to get a toehold in the global marketplace. The sector is blossoming due to innovations in stem cell therapy and tissue engineering. North America accounted for nearly 50 percent of revenue share of global market revenues for regenerative medicines in 2016. Europe is second, at US$24 billion, with Germany leading the region.
A new bio-ink for 3D printing with stem cell
Scientists at the University of Bristol have developed a new kind of bio-ink, which could eventually allow the production of complex tissues for surgical implants. The new stem cell-containing bio ink allows 3D printing of living tissue, known as bio-printing. The new bio-ink contains two different polymer components: a natural polymer extracted from seaweed, and a sacrificial synthetic polymer used in the medical industry, and both had a role to play. The synthetic polymer causes the bio-ink to change from liquid to solid when the temperature is raised, and the seaweed polymer provides structural support when the cell nutrients are introduced. The team was able to differentiate the stem cells into osteoblasts – a cell that secretes the substance of bone – and chondrocytes – cells that have secreted the matrix of cartilage and become embedded in it – to engineer 3D printed tissue structures over five weeks, including a full-size tracheal cartilage ring.
Scientists from the Universidad Carlos III de Madrid (UC3M), CIEMAT (Center for Energy, Environmental and Technological Research), Hospital General Universitario Gregorio Marañón, in collaboration with the firm BioDan Group, have presented a prototype for a 3D bioprinter that can create totally functional human skin. This skin is adequate for transplanting to patients or for use in research or the testing of cosmetic, chemical, and pharmaceutical products.
This new human skin is one of the first living human organs created using bioprinting to be introduced to the marketplace. It replicates the natural structure of the skin, with a first external layer, the epidermis with its stratum corneum, which acts as protection against the external environment, together with another thicker, deeper layer, the dermis. This last layer consists of fibroblasts that produce collagen, the protein that gives elasticity and mechanical strength to the skin.
Stem Cells for Muscular Dystrophies
An orphan disease is a rare disease (according to US criteria, a disease that affects fewer than 200,000 people) or a common disease that has been ignored. But, the true definition not known by many is that a disease category that has not been taken up by any pharmaceutical industry to research on as it provides little financial incentive for the private sector to make and market medicines to treat or cure. Duchenne Muscular Dystrophy (DMD) is one such category in India that is totally not recognized by any healthcare schemes or research initiatives or NGOs or clinicians communities, worth a consideration for offering solace/treatment options to the suffering society. First visit to the doctor by the worried family is usually directed to a Neuro-physician, who would categorically declare that the affected kid will die soon and so medically advised to go home! Such is the level of compassion or practice or medical knowledge in the society that we are in.
Despite the urgent need for research in Orphan diseases, also requires a multidisciplinary personalized approach like a community with participating, practicing Scientists, Clinicians and Parents of the affected kids in order to find innovative medical solutions gathering the expertise into centers of expertise.
Trying to get the facts, it is probable that Orphan diseases will never benefit from a specific drug or any available therapy, need for alternative research lines like Stem cells repairing the continuously degenerating muscles, inflammation associated is the only hope for this disease to be pursued. But, disruptive research has to happen translating into clinical application as patients can’t wait! For once if the investor community believes in scientific breakthroughs alleviating the human suffering as their ROI, it is Paradisso for human kind!
Here, I remain heavy with suffering patients in my thoughts!
January 2017 Transcomm highlights the Orphan disease DMD and possibilities with Stem cells to address the debilitating medical condition. Any application or research with stem cells is possible only if they were captured at the right event and stored in right condition.
So, Dear Readers, Please encourage, educate and evangelize your families, extended families, friends to store stem cells now!
S Dravida Transcell’s CEO
A study conducted by the Indian Society for Clinical Research (ICSR), states that 70 million Indians suffer from life threatening rare diseases. Although we have made immense progress in science and medicine, there is little that is known of the rare diseases prevalent in India, and a paucity of affordable therapy available for these diseases. Children form a part of nearly 50% of the population affected by these diseases, and only 30% of these children, live till the age of five.
Muscular dystrophy is one such rare genetic disorder that affects several in India. An X linked recessive disorder, this disease affects more males than females. While in most developed nations, MD patients survive till the age of 20-23, lack of awareness of this disorder in India has led to most MD children dying at the age of 13-17.
A neuromuscular disorder, which causes degeneration of a set of muscle cells, Muscular Dystrophy starts by destroying the skeletal muscle first, and then progressively deteriorates the internal organs as well. Of the several types of MD, Duchenne MD is the most common. It is caused by a mutation in the DMD gene. Several stem cell therapies have been proposed for DMD.
A loss-of-function mutation in the dystrophin gene, leads to DMD. In a study conducted by Dumont et al (2015), it was found that dystrophin association with a regulator of cell polarity, specifically serine-threonine kinase Mark2 protein, leads to its increased expression in satellite cells (activated muscle stem cells). Thus, absence of dystrophin leads to several intrinsic defects, such as inability to localize cell polarity regulator Pard3. These intrinsic defects, eventually impair muscle regeneration process, because if reduced generation of myogenic progenitors. Hence, it was concluded that the reasons for muscle wasting in DMD can be attributed to impaired regeneration of intrinsic satellite cell dysfunction and myofiber fragility.
In a study conducted by N. Ito et al (2016), it was found that treatment with leukocyte inhibitory factor (LIF) helped to maintain the undifferentiated state of satellite stem cells and also helped to maintain their transplantation efficiency. It was stated that since LIF has been reported to be functionally involved in muscle regeneration, and has alleviated the pathology of a mouse model of DMD, its role `in transplantation efficiency must be analysed. Research also stated that to improve the migration of the transplanted cells, a combination of LIF with other cytokines such as bFGF, would be required.
Anand S, Transcell’s Process Scientist compiles information as:
Ray of hope for Muscular dystrophy patients:
In a recent clinical trial, doctors at AIIMS have found a significant improvement in 20 patients who received stem cell therapy for treating MD.The report of the trial has also been published in the Journal of Stem Cells in its recent issue. Patients suffering from the disease die between ages of 13 to 21 years. According to Dr. B.S. Rajpoot, who led the clinical trial, umbilical cord derived stem cells and IGF1 (a protein that in humans is encoded by the IGF1 gene) was used for stabilization as well as reversal of muscle damage.Initial observations over a period of three months have shown that stability in muscle function has improved and that there was a progressive decline in calf size of the DMD patients up to three years after stem cell transplantation, indicative of increased muscle strength. The added advantage no deleterious effects when using umbilical cord tissue derived stem cells is indicative of the safety of this treatment modality.
B. Tech in Biotechnology,
VIT, Vellore, India
Stem cell therapy new hope to cure muscular Dystrophy: Dr Nandini
Somashekhar, a medical store owner from Mumbai ,who was unable to stand on his feet and walk since past 15 years due to Becker’s Muscular Dystrophy disorder could now carry on his daily routine without any problem, thanks to Mumbai based NeuroGen, Brain and Spine Institute. Somashekhar is the recipient of a stem cell based therapy, which helped him recover within a span of six months. Dr NandiniGokulchandran, deputy director and head of medical services of NeuroGen said stem cell therapy is new hope for patients suffering from so far incurable debilitating disease called Muscular Dystrophy, disorders connected to brain and muscles.
Ryan Benton, a MD patient recently celebrated his 30th birthday thanks to an allogenic adult stem cell transplantation he has undergone. This was the first ever documented case of a MD patient who has lived beyond the normal life expectancy for patients with MD. Due to the restrictions in the US, Ryan had to take several trips to panama to undergo the experimental stem cell therapy. The FDA finally realized the importance of using stem cells for treating MD and granted approval for Ryan to undergo the treatment in the US on a regular basis which led to a more effective reversion of the disease’s progression.
Chances for Muscle Regeneration Improved with Pre-Transplant Cell Treatment
Dr. Shin’ichi Takeda’s research group at the Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry in Kodaira, Japan has successfully shown that muscle stem cells, treated with leukemia inhibitory factor (LIF) are better at forming new muscle fibers when transplanted into the body. Satellite stem cells, found in the muscle have been studied as a therapeutic approach for many years to induce the production of new muscle fibers in people with muscle disease such as Duchenne muscular dystrophy. But studies on the transplantation efficiency of these satellite stem cells in vitro have not yielded positive results. But now, pre-treatment of the satellite cells with LIF, a cytokine could help maintain the undifferentiated state of these cells. According to Dr. Shin’ichi Takeda,“This research enables us to get one step closer to the optimal culture conditions for muscle stem cells”.
Stem Cell Biology As Century Of Biology For Drug Discovery In Neurological Disorders
New revelations into the biology of stem cells have raised expectations for their use in the treatment of neurologic diseases. Formerly, stem cell transplantation was promulgated as tools of replacing cells in central nervous system indicating that transplanted stem cells may decrease deleterious inflammation as well and improve endogenous recovery processes. Generally, neurodegenerative disorders are investigated using animal models, primary cultures and post mortem human brain tissues. The trans-differentiating properties of stem cells into different lineages including of ectodermal neurogenesis make them very fascinating advanced platforms for screening drug molecules property advantageous for neuroregeneration. This is to the extent of considering stem cell platforms for predicting drug molecules role towards specific target receptors of the brain cells. In December 2016 Transcomm, we critically appraise the different types of stem cells, their established therapeutic role, and the applications to which they have been attributed to, with the hope that the evidence shown on the stem cells be translated into clinical reality.
I want to highlight 2016 news on the 13-year study published in The Lancet showing stem cells’ life-altering benefits for multiple sclerosis patients while wishing you all a happy reading and New year 2017.
S Dravida CEO
Patient-derived somatic cells (for example, fibroblasts) can be reprogrammed to generate iPSCs carrying a disease-specific genetic aberration. These cells can then be differentiated into the disease-affected cell type (for example, neurons in neurodegenerative diseases). After the establishment of a cellular disorder model with disease-specific phenotypes, three main strategies are commonly used: high-throughput screening (HTS) of drugs, the candidate drug approach or patient-specific therapy. In HTS, a very large number of compounds are tested on the differentiated cells, followed by phenotype re-evaluation. This method is extremely valuable for identifying novel therapies in vitro, by using large libraries of compounds. By contrast, both the candidate drug approach and the patient-specific therapy use a small number of potential drugs to attenuate the disease. These approaches are useful when the disease mechanism is known and potential therapies are available. Drugs found by both the HTS and candidate drug approaches usually require substantial safety assays before being prescribed to patients, whereas drugs already approved by regulatory agencies can be immediately prescribed for treatment.
Gene therapy using mesenchymal stem cells for Huntington’s disease is showing promise in mouse studies, and preparations are underway to possibly move it into clinical testing. Before the technique might be ready for human trials, however, scientists need to master a few more steps, using larger animal models to investigate the therapy’s safety and likely long-term effects. In the report, “Clinical trial perspective for adult and juvenile Huntington’s disease using genetically-engineered mesenchymal stem cells, ”published in the journal Neural Regeneration Research scientists at University of California Davis Health System summarize the advances so far, discuss the shortcomings of mouse models of Huntington’s disease, and describe preparations for a future clinical trial. Because of their unique biological properties, mesenchymal stem cells have shown tremendous promise in stem cell-based gene therapy approaches in recent years, and applications targeting other neurological diseases, such as ALS and stroke, are now in clinical trials.
These stem cells can be isolated from several easily accessible tissues, and can migrate to brain areas of tissue damage, where they release beneficial factors of their own. They can also be easily manipulated to express other factors.
One of the most important features of these cells, making them such a valuable option for clinical practice, is that they do not elicit an immune response when transplanted from one person to another.
Unmet Medical Needs and Increasing Government Support Boost Global Stem Cells Market
With an ever increasing demand for medical intervention for growing chronic illnesses, the number of R & D activities in the field of mesenchymal stem cells has been rapidly growing. In developed countries like the US, improved government support and access to funding has been fostering stem cell based clinical research. The increasing awareness among the general public has also been adding to this surge in the market for stem cells.
Rapid proliferation of medical tourism facilities across countries such as India, Brazil, China, Malaysia, and Mexico also aids the development of the stem cells market in Latin America and Asia Pacific. Apart from the aforementioned market drivers, a multitude of factors present substantial growth opportunities before the market, such as rising disposable incomes in developing economies, development of the contract research industry, increasing prevalence of neurodegenerative diseases, and the need to replace animal tissue in drug discovery.
North America has been leading the global stem cells market in 2011, followed closely by Europe. High prevalence of neurological and cardiac diseases in the U.S, which, according to the Centers for Disease Control and Prevention, causes more than 50% of the total deaths in the country every year, is a significant factor contributing to the growth of the stem cells market in North America.
The literature analyzed:
It is observed that the neuro-restoration is evolving at an accelerated pace over the past decade. This report has briefly compiled the widespread applicability of stem cells and induced pluripotent stem cells to achieve neurorestoration. Overall, it is noticed that human stem cells and patient derived iPSCs have been instrumental in overcoming the major limitations of animal based research, providing a more profound understanding of the neurodegenerative disorders. Patient derived iPSCs are even better models for understanding the disease pathophysiology and mechanisms because they carry the patient’s genotype, bear the disease mutations and also account for the environmental influences, thereby reducing variables to a large extent. Although it is agreed that stem cell therapy has set off both interests and alarms in the scientific community, its arrival has paved the way for a possible cure with minimized side effects. Personalized medical treatment using iPSCs is the current face of modern medicine and in the present context, less invasive methods of stem cell implantation across the blood brain barrier are being explored. Additionally, constant efforts are being made to scale down the cost and increase the efficacy of the approach.
Neurodegenerative diseases have a series of devastating consequences and the lack or curative therapies often have a high economic impact, thereby placing a huge burden on the society. This is becoming a global health concern. However, recent advances in stem cell biology are serving as a ray of hope, as they are changing the current face of neurodegenerative disease modelling, diagnosis and transplantation therapeutics.
(Marchetto et al., 2011). However, these techniques have their own limitations, although they are informative. By definition, Stem cells are the naive cells of the body with a commendable ability to self-renew, proliferate, differentiate into cells for multi-lineage commitment. Interestingly, their origin can either be fetal, embryonic or adult tissues of the body (iPSCs). Stem cells and iPSCs have been recently finding widespread applications, serving as disease models as well as transplantation and regenerative therapeutics. Every disease has its own characteristic parameter to evaluate- cellular, molecular, anatomical, genotypic and phenotypic attributes. To understand these aspects in vitro, very specific cell types expressing the disease phenotypes are a necessity. Fortunately, most of these requirements have been positively met by the use of stem cell technology.
Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders of the world, lately reported as the 6th major reason for death. It is the leading cause of dementia in the aging population, as the hippocampus, amygdale, neocortex and basal forebrain regions of the patients’ brains are adversely affected, leading to a severe impairment of cognition and memory. The tau hypothesis says that tau protein abnormalities initiate the very disease cascade. In this model, hyperphosphorylated tau begins to pair with other threads of tau forming neurofibrillary tangles inside nerve cell bodies. This leads to microtubules disintegration, destroying the structure of the cell’s cytoskeleton collapsing the neuron’s transport system. Using the mouse models of AD, Blurton-Jones et al in 2009 reported that neural stem cells transplanted in the hippocampus improved memory deficits significantly. Furthermore, observations from animal studies have pointed out that transplanted stem cells migrated and differentiated into cholinergic neurons, astrocytes, and oligodendrocytes. Apart from replacement of the lost neurons, stem cells stimulated endogenous neural precursors, promoted structural neuroplasticity, inhibited proinflammatory cytokines, suppressed neuronal apoptosis and expressed growth factors [Abdel-Salam, 2011]. Yagi et al(2011) is credited to have first derived neurons from patient iPSCs. Since then, a number of studies have been directed towards the approach of patient-specific iPSC derived AD modelling which have resulted in positive outcomes.
PARKINSON’S DISEASE (PD)
Parkinson’s disease ranks second after AD in being the most common and widely prevalent neurodegenerative disorder inflicting almost 1% of the aging population globally. It is typically a disease of the basal ganglia characterized by a progressive degeneration of the dopaminergic neurons in the substantia nigra. This leads to motor dysfunction. The presence of lewy bodies (a-synuclein aggregates) which further promotes neural death is another major hallmark of this disease. The currently available therapies for PD only address the symptoms but do not cure the illness.
Over the last two decades, preclinical and clinical trials in PD patients have demonstrated that stem cell therapy of human embryonic mesencephalic tissue has the capacity to reinnervate the striatum. In fact, PD has emerged as the best-suited neurodegenerative diseases for stem cell therapy (Rosser et al., 2007 and Kim et al., 2009). The basic essence of stem cell therapy in PD is their ability to differentiate into dopaminergic neurons. Very encouragingly, Soldner and colleagues’ finding in 2009 that fibroblasts from PD patients can be reprogrammed to differentiate into dopaminergic neurons was a turning point in the clinical area of PD. However, despite the impressive potential of stem cell therapy in PD, there is always a risk of the serious graft-induced dyskinesis involved, which are being carefully evaluated.
AMYOTROPHIC LATERAL SCLEROSIS(ALS)
ALS is a fatal neurodegenerative disease characterised by the death of the upper and lower motor neurons with subsequent muscular paralysis and atrophy. Compared to other neurodegenerative diseases, certain features of ALS make it more challenging to experiment stem cell therapy. The most important aspect is the unknown pathogenesis, followed by the lack of knowledge on how the disease spreads in the human body. Choosing the ideal site to implant stem cell is difficult without answers to the above questions. Theoretically, the objective of stem cell therapy in ALS would be to substitute the motor neurons. Further, the fundamental strategies of stem cell therapy in ALS consist of the regulation of inflammation and the expression of neurotrophic factors.
Transplantation therapy employing stem cells can be effectively used as a therapeutic measure to deal with the devastating disease. Mesenchymal stem cells and hematopoietic stem cells have been efficiently employed as transplants in the affected spinal cord and have favourably supported ALS management (Mazzini et al., 2012). However, studies were conducted on a small group of patients and thus thorough research continues so as to apply the same for a larger pool of patients. Neural stem cells (NSCs) Embryonic stem cells (ESCs), glial- restricted progenitor cells (GRPs), and induced pluripotent stem cells (iPSCs) also offer a potential alternative for transplantation approaches and can be used (Traub et al., 2011). Stem cell therapy has been an area of debate for a long time. The beneficial aspects cannot be overlooked, but extensive clinical trials are in progress so as to generate an effective treatment and possible cure for ALS in the near future.
Brain stroke and the role of stem cells in treating it
In the United States alone, some 800,000 people suffer from a brain stroke each year and close to 7 million are chronic stroke patients. With a population of 1.5 billion the burden of stroke on Indian society is considered to be significant. Increasing incidences of lifestyle diseases like diabetes and hypertension are also triggers for stroke in men and women. Stroke is the second most common cause of death in India reported by a reputed multi-center study carried out in Chennai. The recent report by the Asia Pacific Heart Rhythm Society cites that the incidence of paralysis and stroke in India is increasing significantly by almost 50% every year with a very distressing fact that 40% die after a major stroke, 30% need full support and more than 50 % do not go back to work.
Strokes can fall into any of the two categories (i) Ischemic or (ii) Hemorrhagic. Approximately 87% of all the strokes tend to be ischemic in nature while the rest are hemorrhagic. The strokes are characterized by clot formation in a blood vessel supplying blood to a specific part of the brain or when there is a burst blood vessel which would then bleed into the brain and kill brain cells. This clot formation/internal bleeding eventually leads to very intensive damage of the affected area. Depending on the area of the brain in which the clot has occurred and its magnitude, it might lead to specific loss of function. The most common loss of functions associated with stroke are cognitive and motor. While approved therapeutic interventions for treating stroke such as administering tPA (tissue plasminogen activator) to dissolve the clot that blocks the flow of blood to the brain, exist, they have to be administered within a few hours of the occurrence of the stroke failing which they would be ineffective.
This poses a huge problem for patients who fail to receive the treatment immediately after stroke. A majority of such patients end up with disabilities. While there are documented cases wherein the lost ability is restored, the incidence of such cases is very low and typically happens over an extended period of time, which could only add to the discomfort of the patient.
Recent studies in the field of regenerative stem cell medicine have shown that administering stem cells to stroke patients helped improve restoration of neurological function. Autologous stem cell transplants have proved to be safe and promising in treating stroke patients, while allogenic stem cells could be developed as druggable tools to treat stroke. We at Transcell strongly believe that given the ever growing importance of stem cells in treating debilitating conditions such as stroke, cancers and other disorders, the general public should be made aware of cryopreserving their loved ones stem cells for use in the future.
Stem cells shown safe, beneficial for chronic stroke patients
Injecting modified, human, adult stem cells directly into the brains of chronic stroke patients proved not only safe but effective in restoring motor function, according to the findings of a small clinical trial led by Stanford University School of Medicine investigators. The patients, all of whom had suffered their first and only stroke between six months and three years before receiving the injections, remained conscious under light anesthesia throughout the procedure, which involved drilling a small hole through their skulls. The next day they all went home.
Although more than three-quarters of them suffered from transient headaches afterward — probably due to the surgical procedure and the physical constraints employed to ensure its precision — there were no side effects attributable to the stem cells themselves, and no life-threatening adverse effects linked to the procedure used to administer them, according to a paper, published online June 2 in Stroke, that details the trial’s results.
Thousands of lives a year could be changed thanks to a pilot research study by Imperial College which involves injecting a patient’s stem cells into their brain.
Doctors said the procedure could become routine in ten years after larger trials to examine its effectiveness in a wider group of patients.
Dr Madina Kara, Neuroscientist at The Stroke Association, said: “In the UK, someone has a stroke every three and half minutes, and around 58% of stroke survivors are left with a disability. One of the few existing treatments which can limit brain damage caused by stroke is thrombolysis. However, this drug can only be used to treat strokes caused by blood clots and must be administered within the first 4.5 hours after a stroke. There is an urgent need for alternative treatments to help prevent the debilitating impact of stroke.
Previous studies have shown that a type of stem cell, called CD34+ cells, shows promise to aid stroke recovery. These latest results suggest that this type of treatment could be administered safely and we’re looking forward to seeing the outcomes of further studies to see exactly how they are aiding recovery.
This is one of the most exciting recent developments in stroke research. It’s still early days in stem cell research but these findings could lead to new treatments for stroke patients in the future.”
-the Daily Telegraph website
Since it’s inception a few five years ago, Transcell’s commitment to reach the needy patient population through translating adult stem cell technologies has become nothing short of a movement led by my team at all levels. It has become a collective vision of my Research, Operations (including of Storage), Accounts, Sales & Marketing team of what we stand for and believe in as a Company today, engaging our mission to promote stem cell storage today for better medicines to people of India, who need them now and tomorrow.
By integrating the purpose of storing stem cells with the need effectively communicated through our in-house research data and the real stories published , we intend to connect with our stakeholders on the meaning behind what we are upto in a scientific way. The purpose of our existence is to contribute effectively translating research to clinics in our life time strongly believing:
Don’t Climb a Mountain with an Intention that the World Should See You. Climb the Mountain with the Intention to See the World.
This is our story:
A German once visited a temple under construction where he saw a sculptor making an idol of God…
Suddenly he noticed a similar idol lying nearby…
Surprised, he asked the sculptor, “Do you need two statues of the same idol?”
“No,” said the sculptor
without looking up, “We need only one, but the first one got damaged at the last stage…”
The gentleman examined the idol and found no apparent damage…
“Where is the damage?” he asked.
“There is a scratch on the nose of the idol.” said the sculptor, still busy with his work….
“Oh… and Where are you going to install the idol?”
The sculptor replied that it would be installed on a pillar twenty feet high…
“If the idol is that far who is going to know that there is a scratch on the nose?” the gentleman asked.
The sculptor stopped work, looked up at the gentleman, smiled and said,
“I will know it…”
The desire to excel is exclusive of the fact whether someone else appreciates it or not.
“Excellence” is a drive from the inside, not outside.
Excellence is not for someone else to notice but for your own satisfaction and efficiency.
Dr S Dravida CEO